Peter J. Hosein
Expertise in
16
conditions

Dr. Peter J. Hosein

Oncology
1475 Northwest 12th Avenue, 
Miami, FL 
Offers Telehealth
Expertise in
16
conditions
1475 Northwest 12th Avenue, 
Miami, FL 

Overview

Peter Hosein is an Oncologist practicing medicine in Miami, Florida.

Dr. Hosein is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Dihydropyrimidine Dehydrogenase Deficiency, Familial Pancreatic Cancer, Pancreaticoduodenectomy, and Pancreatectomy.

He is actively involved in clinical research, co-authoring 73 peer reviewed articles and participating in 10 clinical trials.

Graduate Institution

University Of The West Indies Faculty Of Medicine - 2001

Residency

University of Miami - Jackson Memorial Hospital, Internal Medicine - 2007

Specialties

Oncology

Licenses

Internal Medicine in KY

Fellowships

Jackson Memorial Hospital Division of Hematology/Oncology, Hematology/Oncology - 2010

Hospital Affiliations

Jackson Health System

Languages Spoken

English
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Guardian Life Insurance Company
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Icare Independent Care Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetLife
  • PPO
Neighborhood
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

1475 Northwest 12th Avenue, Miami, FL 33136
Other Locations
1425 Northwest 10th Avenue, Floor 3, Miami, FL 33136

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 2 Single-Arm Study of M6620 in Combination With Irinotecan in Patients With Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer
A Phase 2 Single-Arm Study of M6620 in Combination With Irinotecan in Patients With Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug
Study Drugs: Berzosertib, Irinotecan
Study Phase: Phase 2
A Phase I/II Study of Indoximod in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Adenocarcinoma of the Pancreas
A Phase I/II Study of Indoximod in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Adenocarcinoma of the Pancreas
Enrollment Status: Completed
Publish Date: April 03, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers
A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Atezolizumab, Cobimetinib, Varlilumab
Study Phase: Phase 2
Precision Promise Platform Trial for Metastatic Pancreatic Cancer
Precision Promise Platform Trial for Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug
Study Drugs: Gemcitabine, Nab-paclitaxel, SM-88, mFOLFIRINOX
Study Phase: Phase 3
A Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife® System for the Ablation of Unresectable Stage 3 Pancreatic Adenocarcinoma
A Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife® System for the Ablation of Unresectable Stage 3 Pancreatic Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2025
Intervention Type: Drug, Device
Study Drug: Modified FOLFIRINOX
Study Phase: Phase 3
Ramucirumab Plus Irinotecan in Patients With Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
Ramucirumab Plus Irinotecan in Patients With Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
Enrollment Status: Completed
Publish Date: June 25, 2024
Intervention Type: Genetic, Drug
Study Drugs: Irinotecan, Ramucirumab
Study Phase: Phase 2
A Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response (DDR) Pathway Deficient Neoplasms (UF-STO-ETI-001)
A Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response (DDR) Pathway Deficient Neoplasms (UF-STO-ETI-001)
Enrollment Status: Completed
Publish Date: September 15, 2023
Intervention Type: Drug
Study Drug: Niraparib
Study Phase: Phase 2
A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers
A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers
Enrollment Status: Terminated
Publish Date: August 25, 2023
Intervention Type: Device, Drug
Study Phase: Phase 1
Phase 1a First-in-Human Study of Safety and Tolerability of ASV® AGEN2017 With QS-21 Stimulon® Adjuvant as a Single Agent in Subjects With Solid Tumor at Risk of Relapse Undergoing Observation as SOC Following Complete Surgical Resection
Phase 1a First-in-Human Study of Safety and Tolerability of ASV® AGEN2017 With QS-21 Stimulon® Adjuvant as a Single Agent in Subjects With Solid Tumor at Risk of Relapse Undergoing Observation as SOC Following Complete Surgical Resection
Enrollment Status: Completed
Publish Date: December 02, 2021
Intervention Type: Biological
Study Phase: Phase 1
View 8 Less Clinical Trials

73 Total Publications

IL1RAP-expressing myeloid-stromal networks represent a therapeutic vulnerability to improve chemoimmunotherapy sensitivity in pancreatic cancer.
IL1RAP-expressing myeloid-stromal networks represent a therapeutic vulnerability to improve chemoimmunotherapy sensitivity in pancreatic cancer.
Journal: JCI insight
Published: June 22, 2026
Similar Doctors
Expertise in
57
conditions
Dr. Ricardo J. Komotar
Oncology | Neurosurgery
Expertise in
57
conditions
Dr. Ricardo J. Komotar
Oncology | Neurosurgery
Referral may be required
1295 Northwest 14th Street, 
Miami, FL 
 (0.1 miles away)
305-243-6946
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ricardo Komotar is an Oncologist and a Neurosurgery provider practicing medicine in Miami, Florida. Dr. Komotar is highly rated in 57 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Meningioma, Glioblastoma, Awake Craniotomy, and Posterior Fossa Decompression. Dr. Komotar is currently accepting new patients.

Expertise in
25
conditions
Expertise in
25
conditions
Referral may be required

Baptist Health Miami Cancer Institute

8900 N Kendall Dr, 
Miami, FL 
 (10.7 miles away)
786-345-7208
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Manmeet Ahluwalia is an Oncologist practicing medicine in Miami, Florida. Dr. Ahluwalia is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Glioblastoma, Astrocytoma, and Glioma. Dr. Ahluwalia is currently accepting new patients.

Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required
1425 Northwest 10th Avenue, 
Miami, FL 
 (0.2 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Emanuela Palmerini is an Oncologist practicing medicine in Miami, Florida. Dr. Palmerini is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Adult Soft Tissue Sarcoma, Osteosarcoma, Chondrosarcoma, and Ewing Sarcoma. Dr. Palmerini is currently accepting new patients.

Frequently Asked Questions about Dr. Peter J. Hosein

How do I make an appointment with Dr. Peter J. Hosein?

You can book an appointment with Dr. Peter J. Hosein by calling their office at 305-243-5302. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Peter J. Hosein a top-rated expert for Pancreatic Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Peter J. Hosein is classified as an Elite expert for Pancreatic Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Peter J. Hosein specialize in?

While Dr. Peter J. Hosein is a Oncology, they have specific expertise in Pancreatic Cancer, Dihydropyrimidine Dehydrogenase Deficiency, and Familial Pancreatic Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Peter J. Hosein participate in research or clinical trials?

Yes. Dr. Peter J. Hosein has published 73 articles and abstracts on conditions like Pancreatic Cancer. You can view a list of Dr. Peter J. Hosein's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Peter J. Hosein accept my insurance?

Dr. Peter J. Hosein accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 305-243-5302 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hosein's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 55 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile